Table 1.
Chemical Structure | Cell Line | Activity | Mechanism | Reference |
---|---|---|---|---|
Kidney cancer cells (HEK 293) | LC50 (µM) | Topoisomerase IIR catalytic inhibitors. The apoptotic effect in the G1/S phase. |
[9] | |
Breast cancer cells (MCF7) | 15 at both cell lines | |||
IC50 (µM) | Induce apoptosis. Bind with DNA through intercalation. |
[10] | ||
Cervix cancer cells (HeLa) | 2.88 ± 0.15 | |||
Breast cancer cells (MCF-7) | 0.75 ± 0.07 | |||
Lung cancer cells (A549) | 4.37 ± 0.07 | |||
Liver cancer cells (HepG2) | 2.91 ± 0.11 | |||
IC50 (µM) | Focal Adhesion Kinase (FAK) inhibition. Arrest cells in the G2/M phase of the cell cycle. Retard cell growth |
[12] | ||
Brain (U87-MG) | 0.37±0.04 | |||
Colon (HCT-116) | 0.31±0.18 | |||
Breast (MDA-MB)-231 | 1.08±0.45 | |||
Prostate (PC-3) | 1.27±0.28 | |||
IC50 (µM) | Decreases angiogenesis in the peritoneum of EAT bearing mice. | [14] | ||
Cervical (HeLa) | 25.3 | |||
GI50 (µM) | Cyclin-dependent kinase 6 (CDK6) inhibition and induce cancer cell apoptosis. | [15] | ||
Colon (HCT-116) | 3.0 | |||
Breast (MCF-7) | 40 | |||
IC50 (µM) | Selective inhibitor for the HUVECs. Activation of p38 signaling pathway. |
[16] | ||
Human umbilical vein endothelial cells (HUVECs) | 0.4 | |||
Smooth muscle cells (SMCs) | 5.5 | |||
IC50 (µM) | Exhibited excellent inhibitory activity on tumor growth in vivo | [17] | ||
Human myeloid leukemia cells (HL-60) | 0.2 | |||
Human myeloid leukemia cells (K562) | 1 | |||
Human myeloid leukemia cells (K562R) (multidrug-resistant cells) | 0.9 | |||
Human prostate carcinoma cells (PC-3) | 3.1 | |||
Human breast carcinoma cells (MCF-7) | 10.6 | |||
Human esophageal carcinoma cells (ECA-109) | 3.8 | |||
Human hepatocarcinoma cells (BEL-7402) | 1.2 | |||
Human non-small lung cancer cells (A549) | 1.3 | |||
IC50 (µM) | Inhibit tubulin polymerization and arrest cell cycle at G2/M phase | [21] | ||
MCF-7 | 9.450±0.292 | |||
H1299 | 7.652±0.215 | |||
HeLa | 6.862±0.144 | |||
B16-F10 | 4.912±0.088 | |||
HUVEC | >50 | |||
IC50 (µM) | Arrest cell cycle at G1 phase and induce apoptosis | [22] | ||
HeLa | 82.83±1.37 | |||
GI50 (µM) | ND Possibly due to dimerized estrogen receptor |
[18] | ||
Cervical (HeLa) | 0.36 | |||
Breast (MDA-MB-231) | 0.30 | |||
Renal cancer (ACHN) | 0.38 | |||
IC50 (µM) | c-MYC G-quadruplex DNA stabilizers | [19] | ||
Nasopharyngeal carcinoma (CNE-1) | 1.1± 0.1 | |||
IC50 (µM) | Aurora kinase inhibition | [20] | ||
breast cancer (MDA-MB-231) | 0.38±0.08 | |||
prostate cancer (PC3) | 1.09 ±0.24 | |||
neuroblastoma (SH-SY5Y) | 0.77±0.12 | |||
IC50 (µM) | Inhibit BRAFV600E kinase | [23] | ||
NCI 60 | 2.4 | |||
LOX IMVI | 1.75 | |||
MALME-3M | 1.69 | |||
M14 | 1.76 | |||
MDA-MB-435 | 1.97 | |||
SK-MEL-2 | 2.21 | |||
SK-MEL-28 | 2.13 | |||
SK-MEL-5 | 1.60 | |||
UACC-257 | 2.08 | |||
UACC-62 | 1.85 | |||
IC50 (µM) | Inhibit GSK-3β | [24] | ||
Caco-2 | 4.67 ± 0.11 | |||
HCT-116 | 16.78 ± 0.59 | |||
HeLa | 6.87 ± 0.32 | |||
MCF-7 | 0.38 ± 0.04 | |||
IC50 (µM) | Anti-proliferative | [11] | ||
Melanoma (human A375) | 16.1±0.5 | |||
Melanoma (mouse B16) | 31.6±1.1 | |||
Cervical (HeLa) |
IC50 (µM) >25 for all the cell lines |
ND | [13] | |
Colon (LS180) | ||||
Breast (MCF-7) | ||||
Jurkat cells | ||||
IC50 (µΜ) | ND | [25] | ||
A549 | 0.93 ± 0.34 | |||
PC3 | 0.83 ± 0.27 | |||
PANC | 0.063 ± 0.09 | |||
ASPC-1 | 0.062 ± 0.013 |
Note: Values are means of three experiments.
Abbreviation: LC50, The concentration required to kill half the cells in the cell culture; IC50, Compound concentration required to inhibit tumor cell proliferation by 50%; GI50, The concentration of drug causing 50% inhibition of cell growth; ND, Not determined.